| Date Amouzou, NP | |
|
16101 Grebe St, Bennington, NE 68007-1255 | |
| (402) 517-0839 | |
| Not Available |
| Full Name | Date Amouzou |
|---|---|
| Gender | Male |
| Speciality | Nurse Practitioner |
| Experience | 8 Years |
| Location | 16101 Grebe St, Bennington, Nebraska |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1942755954 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | 112098 (Nebraska) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Chi Health Immanuel | Omaha, NE | Hospital |
| Chi Health Midlands | Papillion, NE | Hospital |
| Chi Health Mercy Council Bluffs | Council bluffs, IA | Hospital |
| Entity Name | Alegent Creighton Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548287907 PECOS PAC ID: 1951210418 Enrollment ID: O20040407001314 |
News Archive
Hillenbrand reported third quarter 2010 revenue of $205.8 million, a $47.1 million (30 percent) increase over the prior year, due primarily to the inclusion of revenue generated by K-Tron International, which Hillenbrand acquired April 1, 2010. Business acquisition costs and the impact of purchase accounting were the primary drivers of a $12.1 million (48 percent) decrease in net income from the prior year and a $0.19 (46 percent) decrease in earnings per share, from $0.41 to $0.22.
Diesel particle pollution inside urban school buses may be worse than levels found in the surrounding roadway air, according to a study by scientists at the University of California. The report appears in the April 15 issue of the American Chemical Society's journal Environmental Science & Technology.
AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces achievement of a major milestone with the completion of the active treatment portion of its Phase 1 clinical trial with its lead compound, AHRO-001. The Phase 1 study objective is to evaluate the safety, tolerability and pharmacokinetics of AHRO-001 in healthy volunteers. The clinical study is being conducted in Russia with AtheroNova's licensing partner, OOO CardioNova.
EFT BioTech Holdings, Inc., a proprietary e-commerce solutions Company providing "made in the USA" health, beauty and nutriceutical products under the EFT brand to its affiliate member network, boasting almost one million members strong, reports Secretary Hillary Clinton fully engaged with Vietnamese counterparts for progress, prosperity and peace at the same time EFT reports standing room only of over 2,000 people in Vietnam at its first major affiliate membership drive in the region.
Idiopathic pulmonary fibrosis (IPF) is a common and severe lung disease of unknown cause and with no proven therapies. But researchers are pushing forward in investigating new clues to the development and effective treatment of IPF, according to a special symposium presented in The American Journal of the Medical Sciences (AJMS), official journal of the Southern Society for Clinical Investigation (SSCI).
› Verified 9 days ago
| Entity Name | Align Care |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1730466228 PECOS PAC ID: 7315104916 Enrollment ID: O20120215000869 |
News Archive
Hillenbrand reported third quarter 2010 revenue of $205.8 million, a $47.1 million (30 percent) increase over the prior year, due primarily to the inclusion of revenue generated by K-Tron International, which Hillenbrand acquired April 1, 2010. Business acquisition costs and the impact of purchase accounting were the primary drivers of a $12.1 million (48 percent) decrease in net income from the prior year and a $0.19 (46 percent) decrease in earnings per share, from $0.41 to $0.22.
Diesel particle pollution inside urban school buses may be worse than levels found in the surrounding roadway air, according to a study by scientists at the University of California. The report appears in the April 15 issue of the American Chemical Society's journal Environmental Science & Technology.
AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces achievement of a major milestone with the completion of the active treatment portion of its Phase 1 clinical trial with its lead compound, AHRO-001. The Phase 1 study objective is to evaluate the safety, tolerability and pharmacokinetics of AHRO-001 in healthy volunteers. The clinical study is being conducted in Russia with AtheroNova's licensing partner, OOO CardioNova.
EFT BioTech Holdings, Inc., a proprietary e-commerce solutions Company providing "made in the USA" health, beauty and nutriceutical products under the EFT brand to its affiliate member network, boasting almost one million members strong, reports Secretary Hillary Clinton fully engaged with Vietnamese counterparts for progress, prosperity and peace at the same time EFT reports standing room only of over 2,000 people in Vietnam at its first major affiliate membership drive in the region.
Idiopathic pulmonary fibrosis (IPF) is a common and severe lung disease of unknown cause and with no proven therapies. But researchers are pushing forward in investigating new clues to the development and effective treatment of IPF, according to a special symposium presented in The American Journal of the Medical Sciences (AJMS), official journal of the Southern Society for Clinical Investigation (SSCI).
› Verified 9 days ago
| Entity Name | Keen Minds Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568048726 PECOS PAC ID: 9032518717 Enrollment ID: O20210528002252 |
News Archive
Hillenbrand reported third quarter 2010 revenue of $205.8 million, a $47.1 million (30 percent) increase over the prior year, due primarily to the inclusion of revenue generated by K-Tron International, which Hillenbrand acquired April 1, 2010. Business acquisition costs and the impact of purchase accounting were the primary drivers of a $12.1 million (48 percent) decrease in net income from the prior year and a $0.19 (46 percent) decrease in earnings per share, from $0.41 to $0.22.
Diesel particle pollution inside urban school buses may be worse than levels found in the surrounding roadway air, according to a study by scientists at the University of California. The report appears in the April 15 issue of the American Chemical Society's journal Environmental Science & Technology.
AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces achievement of a major milestone with the completion of the active treatment portion of its Phase 1 clinical trial with its lead compound, AHRO-001. The Phase 1 study objective is to evaluate the safety, tolerability and pharmacokinetics of AHRO-001 in healthy volunteers. The clinical study is being conducted in Russia with AtheroNova's licensing partner, OOO CardioNova.
EFT BioTech Holdings, Inc., a proprietary e-commerce solutions Company providing "made in the USA" health, beauty and nutriceutical products under the EFT brand to its affiliate member network, boasting almost one million members strong, reports Secretary Hillary Clinton fully engaged with Vietnamese counterparts for progress, prosperity and peace at the same time EFT reports standing room only of over 2,000 people in Vietnam at its first major affiliate membership drive in the region.
Idiopathic pulmonary fibrosis (IPF) is a common and severe lung disease of unknown cause and with no proven therapies. But researchers are pushing forward in investigating new clues to the development and effective treatment of IPF, according to a special symposium presented in The American Journal of the Medical Sciences (AJMS), official journal of the Southern Society for Clinical Investigation (SSCI).
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Date Amouzou, NP 7261 Mercy Rd, Omaha, NE 68124-2311 Ph: () - | Date Amouzou, NP 16101 Grebe St, Bennington, NE 68007-1255 Ph: (402) 517-0839 |
News Archive
Hillenbrand reported third quarter 2010 revenue of $205.8 million, a $47.1 million (30 percent) increase over the prior year, due primarily to the inclusion of revenue generated by K-Tron International, which Hillenbrand acquired April 1, 2010. Business acquisition costs and the impact of purchase accounting were the primary drivers of a $12.1 million (48 percent) decrease in net income from the prior year and a $0.19 (46 percent) decrease in earnings per share, from $0.41 to $0.22.
Diesel particle pollution inside urban school buses may be worse than levels found in the surrounding roadway air, according to a study by scientists at the University of California. The report appears in the April 15 issue of the American Chemical Society's journal Environmental Science & Technology.
AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces achievement of a major milestone with the completion of the active treatment portion of its Phase 1 clinical trial with its lead compound, AHRO-001. The Phase 1 study objective is to evaluate the safety, tolerability and pharmacokinetics of AHRO-001 in healthy volunteers. The clinical study is being conducted in Russia with AtheroNova's licensing partner, OOO CardioNova.
EFT BioTech Holdings, Inc., a proprietary e-commerce solutions Company providing "made in the USA" health, beauty and nutriceutical products under the EFT brand to its affiliate member network, boasting almost one million members strong, reports Secretary Hillary Clinton fully engaged with Vietnamese counterparts for progress, prosperity and peace at the same time EFT reports standing room only of over 2,000 people in Vietnam at its first major affiliate membership drive in the region.
Idiopathic pulmonary fibrosis (IPF) is a common and severe lung disease of unknown cause and with no proven therapies. But researchers are pushing forward in investigating new clues to the development and effective treatment of IPF, according to a special symposium presented in The American Journal of the Medical Sciences (AJMS), official journal of the Southern Society for Clinical Investigation (SSCI).
› Verified 9 days ago
Kristina L Wallingford, APRN Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 7941 N 152nd St, Bennington, NE 68007 Phone: 402-553-4717 | |
Mr. Bakir-wena Komla Badjaglana, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 14822 Grebe St, Bennington, NE 68007 Phone: 402-515-4044 | |
Jenny N Dankert, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 15009 Mormon St, Bennington, NE 68007 Phone: 402-216-8905 |